Abstract
Large numbers and quantities of different, small RNA molecules are present in the cytoplasm of animal and plant cells. One subclass of these molecules is represented by the noncoding microRNAs. Since their discovery in the 1990s a multitude of basic information has accumulated, which has identified their function in post-transcriptional control, either via degradation or translational inhibition of target mRNAs. This function is in most of the cases a finetuning of gene expression, working in parallel with transcriptional regulatory processes. MicroRNA expression profiles are highly dynamic during embryonic development and in adulthood. Misexpression of microRNAs can perturb embryogenesis, organogenesis, tissue homeostasis and the cell cycle. Evidence from gain- and loss-of function studies indicates roles for microRNAs in pathophysiologic states including cardiac hypertrophy, muscle dystrophy, hepatitis infection, diabetes, Parkinson syndrome, hematological malignancies and other types of cancer. In this review, we focus on studies addressing the role of various microRNAs in heart, muscle, liver, pancreas, central nervous system, and hematopoiesis.
Keywords: microRNA, development, disease, cell cycle
Current Molecular Medicine
Title: MicroRNAs in Organogenesis and Disease
Volume: 8 Issue: 8
Author(s): Naisana S. Asli, Mara E. Pitulescu and Michael Kessel
Affiliation:
Keywords: microRNA, development, disease, cell cycle
Abstract: Large numbers and quantities of different, small RNA molecules are present in the cytoplasm of animal and plant cells. One subclass of these molecules is represented by the noncoding microRNAs. Since their discovery in the 1990s a multitude of basic information has accumulated, which has identified their function in post-transcriptional control, either via degradation or translational inhibition of target mRNAs. This function is in most of the cases a finetuning of gene expression, working in parallel with transcriptional regulatory processes. MicroRNA expression profiles are highly dynamic during embryonic development and in adulthood. Misexpression of microRNAs can perturb embryogenesis, organogenesis, tissue homeostasis and the cell cycle. Evidence from gain- and loss-of function studies indicates roles for microRNAs in pathophysiologic states including cardiac hypertrophy, muscle dystrophy, hepatitis infection, diabetes, Parkinson syndrome, hematological malignancies and other types of cancer. In this review, we focus on studies addressing the role of various microRNAs in heart, muscle, liver, pancreas, central nervous system, and hematopoiesis.
Export Options
About this article
Cite this article as:
Asli S. Naisana, Pitulescu E. Mara and Kessel Michael, MicroRNAs in Organogenesis and Disease, Current Molecular Medicine 2008; 8 (8) . https://dx.doi.org/10.2174/156652408786733739
DOI https://dx.doi.org/10.2174/156652408786733739 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Author Index To Volume 3
Current Topics in Medicinal Chemistry Discovery and Advancement of Farnesyl Transferase Inhibitors as Potential Anticancer Therapeutic Agents: SCH 66336 a Case Study
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Chromatin Remodeling Agents for Cancer Therapy
Reviews on Recent Clinical Trials Gastrointestinal Non Colorectal Cancer. Do Elderly Patients Need a Specific Management?
Anti-Cancer Agents in Medicinal Chemistry Toll-Like Receptors in Human Multiple Myeloma: New Insight into Inflammation-Related Pathogenesis
Current Molecular Medicine The Urokinase Receptor as a Potential Target in Cancer Therapy
Current Pharmaceutical Design The Ubiquitin-Proteasome Pathway and Resistance Mechanisms Developed Against the Proteasomal Inhibitors in Cancer Cells
Current Drug Targets The Parathyroid Hormone Receptorsome and the Potential for Therapeutic Intervention
Current Drug Targets Discovery of Potent Bruton’s Tyrosine Kinase Inhibitors Using Ligand Based Modeling
Anti-Cancer Agents in Medicinal Chemistry Wnt/β-Catenin/LEF-1 Signaling in Chronic Lymphocytic Leukemia (CLL): A Target for Current and Potential Therapeutic Options
Current Cancer Drug Targets Refractory Angina Pectoris: Lessons from the Past and Current Perspectives
Current Pharmaceutical Design Endothelial and Circulating Progenitor Cells in Hematological Diseases and Allogeneic Hematopoietic Stem Cell Transplantation
Current Medicinal Chemistry Acute Phase Proteins In Atherosclerosis (Acute Coronary Syndrome)
Cardiovascular & Hematological Agents in Medicinal Chemistry Hijacking the Hedgehog Pathway in Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Heat Shock Proteins: A Potential Anticancer Target
Current Drug Targets Interferon Therapy in Lung Cancer: Current Perspectives
Current Cancer Therapy Reviews Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia
Anti-Cancer Agents in Medicinal Chemistry Prevention and Treatment of Regimen-Related Mucosal Toxicity
Recent Patents on Anti-Cancer Drug Discovery Laccase Regulators in Anti-fungal Drug Discovery: Dark Lessons from the AIDS-related Pathogen, Cryptococcus
Current Enzyme Inhibition The mTOR Pathway: A New Target in Cancer Therapy
Current Cancer Drug Targets